GSK PLC (GS71.SG)
| Previous Close | 20.75 |
| Open | 20.63 |
| Bid | 20.60 x N/A |
| Ask | 21.05 x N/A |
| Day's Range | 20.60 - 20.66 |
| 52 Week Range | 20.60 - 20.94 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Evening StandardFTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale
GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results. The sale of GSK’s remaining 4% stake raised £1.25 billion, having held 13% following its 2022 demerger of the Panadol and Sensodyne business. Land Securities revealed a smaller full-year loss of £341 million amid “robust” rental growth across its estate.
Yahoo Finance UKTrending tickers: Tesla, Reddit, Walmart and GSK
The latest investor updates on stocks that are trending on Friday.
ReutersGSK raises $1.5 billion from sale of remaining Haleon stake
The sale will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which are part of CEO Emma Walmsley's plans to boost earnings at the drugmaker. GSK sold around 385 million shares at 324 pence each, amounting to a 4.2% stake in Haleon. Friday's sale was at a discount of about 2.5% to Haleon's last close of 332.4 pence on Thursday.
